Status:
COMPLETED
Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Subjects
Eligibility:
MALE
20-55 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to investigate the safety and tolerability of single and multiple oral doses of AZD7295 in healthy male Japanese subjects. This will be done by comparing the eff...
Eligibility Criteria
Inclusion
- Provision of signed, written and dated informed consent
- Healthy male Japanese volunteers aged 20-55 years
- BMI between 18 and 27 kg/m2
- Have negative screens for HIV, hepatitis B and C viruses and syphilis
Exclusion
- Use of prescribed medication within 2 weeks prior to the dose of study medication
- Participation in another study that included drug treatment within 16 weeks before the start of the present study.
- History or presence of gastrointestinal, hepatic or renal disease or a condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
- History of severe food or drug allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged relevant by the investigator.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00818129
Start Date
December 1 2008
End Date
May 1 2009
Last Update
July 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fukuoka, Fukuoka, Japan